Ablevia biotech is Drug Discovery in Austria that focus on therapeutics assist business. Founded in 2018. They cover business area such as developer, selective antibody removal therapeutic, direct inactivation, disease-cause antibody, autoimmune disease, infusible therapeutic, harmful antibody, autoimmune condition, transplant rejection, anti-drug antibody, biotherapeutic, healthcare provider, compound, rare disease, unmet clinical need.
2018
( 6 years old in 2024 )
Therapeutics Assist
-
Maria Jacobi Gasse 1
MQM 3.2
Vienna, 1030
Austria
Private
developerselective antibody removal therapeuticdirect inactivationdisease-cause antibodyautoimmune diseaseinfusible therapeuticharmful antibodyautoimmune conditiontransplant rejectionanti-drug antibodybiotherapeutichealthcare providercompoundrare diseaseunmet clinical need
* We use standard office opening hours in near Ablevia biotech's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Ablevia Biotech is Drug Discovery business from Austria that founded in 2018 (6 years old in 2024), Ablevia biotech business is focusing on Therapeutics Assist.
Ablevia biotech headquarter office and corporate office address is located in Maria Jacobi Gasse 1 MQM 3.2 Vienna, 1030 Austria.
Ablevia biotech was founded in Austria.
In 2024, Ablevia biotech is currently focus on therapeutics assist sector.
Above is snippet of Google Trends for "therapeutics assist" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Ablevia biotech, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
